Objective:

To summarize recent progress in the application of liquid biopsy technologies in pediatric ALL.

Approach:

Key Findings:

• Liquid biopsy is a minimally invasive tool for real-time disease monitoring and prognostication in pediatric ALL.
• Bone marrow evaluation remains the gold standard for diagnosis and MRD monitoring in pediatric ALL.
• Most liquid biopsy approaches are still in early translational stages.

Interpretation:

Limitations:

• Most liquid biopsy approaches are still in early translational stages.
• Validation in large, prospective pediatric cohorts is essential for clinical implementation.

Conclusion:

Further validation is needed for liquid biopsy technologies in pediatric ALL.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.